Total Valuation
Intellia Therapeutics has a market cap or net worth of CHF1.89B. The enterprise value is $1.65B.
Market CapCHF1.89B
Enterprise Value$1.65B
Share Statistics
Intellia Therapeutics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.57%
Owned by Institutions24.88%
Financial Efficiency
Intellia Therapeutics’s return on equity (ROE) is -0.61 and return on invested capital (ROIC) is -57.67%.
Return on Equity (ROE)-0.61
Return on Assets (ROA)-0.49
Return on Invested Capital (ROIC)-57.67%
Return on Capital Employed (ROCE)-0.60
Revenue Per Employee167.92K
Profits Per Employee-1.29M
Employee Count403
Asset Turnover0.08
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Intellia Therapeutics is ―. Intellia Therapeutics’s PEG ratio is 0.09.
PE Ratio―
PS Ratio14.40
PB Ratio1.45
Price to Fair Value1.45
Price to FCF-2.75
Price to Operating Cash Flow-5.44
PEG Ratio0.09
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 67.67M and earned -412.69M in profits. Earnings per share was -3.81.
Revenue67.67M
Gross Profit51.75M
Operating Income-440.99M
Pretax Income-412.69M
Net Income-412.69M
EBITDA-396.77M
Earnings Per Share (EPS)-3.81
Cash Flow
In the last 12 months, operating cash flow was -363.15M and capital expenditures -473.00K, giving a free cash flow of -363.63M billion.
Operating Cash Flow-363.15M
Free Cash Flow-363.63M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Intellia Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Intellia Therapeutics upcoming earnings date is Jul 30, 2026, TBA (Confirmed).
Last Earnings DateMay 11, 2026
Next Earnings DateJul 30, 2026
Ex-Dividend Date―
Financial Position
Intellia Therapeutics as a current ratio of 5.08, with Debt / Equity ratio of 12.96%
Current Ratio5.08
Quick Ratio5.08
Debt to Market Cap0.07
Net Debt to EBITDA0.16
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Intellia Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Intellia Therapeutics EV to EBITDA ratio is -2.30, with an EV/FCF ratio of -2.57.
EV to Sales13.48
EV to EBITDA-2.30
EV to Free Cash Flow-2.57
EV to Operating Cash Flow-2.61
Balance Sheet
Intellia Therapeutics has CHF375.99M in cash and marketable securities with CHF80.49M in debt, giving a net cash position of CHF295.50M billion.
Cash & Marketable SecuritiesCHF375.99M
Total DebtCHF80.49M
Net CashCHF295.50M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF6.20
Margins
Gross margin is -153.74%, with operating margin of -651.67%, and net profit margin of -609.85%.
Gross Margin-153.74%
Operating Margin-651.67%
Pretax Margin-609.85%
Net Profit Margin-609.85%
EBITDA Margin-586.32%
EBIT Margin-609.85%
Analyst Forecast
The average price target for Intellia Therapeutics is CHF17.06, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF17.06
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count18
Revenue Growth Forecast―
EPS Growth Forecast―